RPL3 and ovarian carcinoma: These data together with recent finding demonstrating that silencing of CBS in ovarian cancer cells is associate to a decrease of NFκB promoter activity7, led us to suppose that the drastic reduction in NFκB activity, observed after 5-FU treatment in Calu-6 cells, is a result of rpL3 mediated CBS down-regulation and IκB-α stabilization.